Connect with us

Digital Health

Oncoscience | Rapamycin in the context of Pascal’s Wager: generative pre-trained transformer perspective

“The ability of the large language models, and other AI systems to make meaningful contributions to academic work may justify future co-authorship on…

Published

on

This article was originally published by BioEngineering

“The ability of the large language models, and other AI systems to make meaningful contributions to academic work may justify future co-authorship on academic perspective, review and research papers.”

Oncoscience

Credit: Oncoscience

“The ability of the large language models, and other AI systems to make meaningful contributions to academic work may justify future co-authorship on academic perspective, review and research papers.”

BUFFALO, NY- December 27, 2022 – A new research perspective was published in Oncoscience (Volume 9) on December 21, 2022, entitled, “Rapamycin in the context of Pascal’s Wager: generative pre-trained transformer perspective.”

Large language models utilizing transformer neural networks and other deep learning architectures demonstrated unprecedented results in many tasks previously accessible only to human intelligence. In this new paper, Dr. Alex Zhavoronkov from Insilico Medicine used the ChatGPT Generative Pre-trained Transformer by OpenAI to discuss the use of rapamycin for anti-aging through the philosophical framework of Pascal’s wager.

“In this article, we collaborate with ChatGPT, an AI model developed by OpenAI to speculate on the applications of Rapamycin, in the context of Pascal’s Wager philosophical argument commonly utilized to justify the belief in god.” — Dr. Alex Zhavoronkov

In response to the query, “Write an exhaustive research perspective on why taking Rapamycin may be more beneficial than not taking Rapamycin from the perspective of Pascal’s wager,” ChatGPT provided the pros and cons for the use of Rapamycin considering the preclinical evidence of potential life extension in animals. This article demonstrates the potential of ChatGPT to produce complex philosophical arguments and should not be used for any off-label use of Rapamycin.

“In conclusion, the decision to take Rapamycin or not is ultimately a personal one, and it will depend on an individual’s values and priorities. From the perspective of Pascal’s wager, taking Rapamycin could potentially provide significant health benefits and extend lifespan, but it also carries the risk of side effects and long-term health problems. Ultimately, the decision should be made in consultation with a healthcare provider, who can provide guidance and advice based on an individual’s specific situation.”  — ChatGPT

 

DOI: https://doi.org/10.18632/oncoscience.571 

Correspondence to: Alex Zhavoronkov Email: alex@insilico.com 

Keywords: artificial intelligence, Rapamycin, philosophy, longevity medicine, Pascal’s Wager
 

About Oncoscience

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:

  • Twitterhttps://twitter.com/OncoscienceJrnl 
  • Facebookhttps://www.facebook.com/Oncoscience 
  • YouTubehttps://www.youtube.com/channel/UCyuhJRF3rNxTJcFhDJ9eK5A 
  • LinkedInhttps://www.linkedin.com/company/oncoscience/ 

 

For media inquiries, please contact media@impactjournals.com.

 

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4

###


artificial intelligence


Digital Health

Keep it Short

By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….

Continue Reading
Markets

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading
Digital Health

Seattle startup Olamedi building platform to automate health clinic communications

A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…

Continue Reading

Trending